Hyundai Pharm Receives Domestic Approval for Phase 2 Clinical Trial of New Diabetes Treatment Drug
[Asia Economy Reporter Chunhee Lee] Hyundai Pharm announced on the 21st that it has received approval from the Ministry of Food and Drug Safety for the domestic Phase 2 clinical trial of the oral type 2 diabetes treatment new drug candidate ‘HDNO-1605 (HD-6277)’.
This Phase 2 clinical trial will be conducted to exploratively verify the efficacy and safety of HD-6277 in patients with type 2 diabetes.
HDNO-1605 (HD-6277) is a type 2 diabetes treatment candidate targeting the GPR40 receptor, which regulates insulin secretion in the body. It is explained to have a low risk of side effects such as hypoglycemia while demonstrating excellent blood sugar control with once-daily administration.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "To Get Revenge on Ex-Girlfriend" US McDonald's Manager Spits on French Fries
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
A Hyundai Pharm official stated, “The commencement of this Phase 2 clinical trial will be an important step closer to developing a new mechanism diabetes drug,” and added, “We expect that the new drug development will provide safe and effective options for medical professionals and patients.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
